• MBX Biosciences started dosing patients in its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide for chronic hypoparathyroidism.
• Phase 2 Avail results were previously presented, with one-year follow-up indicating sustained clinical benefit.
• The Phase 3 study aims to support registration, targeting a therapy that could reduce reliance on standard supplements while keeping calcium controlled.
• The global trial plans to enroll about 160 adults, with a 26-week blinded period followed by a 78-week open-label extension.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270800PRIMZONEFULLFEED9816696) on August 27, 2026, and is solely responsible for the information contained therein.